Heterologous regulation of mu-opioid (MOP) receptor mobility in the membrane of SH-SY5Y cells

Journal of Biological Chemistry

Volumn 289, Issue 41, 2014, Pages 28697-28706

  Carayon, Kévin ^a   Moulédous, Lionel ^a   Combedazou, Anne ^a   Mazères, Serge ^a   Haanappel, Evert ^a   Salomé, Laurence ^a   Mollereau, Catherine ^a  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SH-SY5Y CELLS;

ALPHA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; HETERODIMER; MU OPIATE RECEPTOR; NEUROPEPTIDE FF RECEPTOR; NEUROPEPTIDE Y RECEPTOR; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; CLONIDINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FLUORESCENT DYE; NARCOTIC ANALGESIC AGENT; NEUROPEPTIDE FF, TYR(1)-N-METHYL-PHE(3)-; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; OLIGOPEPTIDE;

ARTICLE; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; CELL MEMBRANE; CELL MEMBRANE TRANSPORT; DIFFUSION; FLUORESCENCE; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; SIGNAL TRANSDUCTION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NERVE CELL; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANALGESICS, OPIOID; CELL LINE, TUMOR; CELL MEMBRANE; CLONIDINE; DIFFUSION; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; FLUORESCENT DYES; GENE EXPRESSION REGULATION; HUMANS; NEURONS; NEUROPEPTIDE Y; OLIGOPEPTIDES; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RECEPTOR CROSS-TALK; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, NEUROPEPTIDE; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 84907646379     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.588558     Document Type: Article

References (79)

1. Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., and Christie, M. J. (2013) Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223-254
2. Chabot-Dore, A. J., Schuster, D. J., Stone, L. S., and Wilcox, G. L. (2014) Analgesic synergy between opioid and α2 adrenergic receptors. Br. J. Pharmacol. 10.1111/bph.12695
3. Harrison, L. M., Kastin, A. J., and Zadina, J. E. (1998) Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. Peptides 19, 1603-1630
4. Mollereau, C., Roumy, M., and Zajac, J. M. (2005) Opioid-modulating Peptides: mechanisms of Action. Curr. Top. Med. Chem. 5, 341-355
5. Ossipov, M. H., Lai, J., King, T., Vanderah, T. W., Malan, T. P., Jr., Hruby, V. J., and Porreca, F. (2004) Antinociceptive and nociceptive actions of opioids. J. Neurobiol. 61, 126-148
6. Massotte, D. (2014) In vivo opioid receptor heteromerization: where do we stand? Br. J. Pharmacol. 10.1111/bph.12702
7. Rozenfeld, R., and Devi, L. A. (2010) Receptor heteromerization and drug discovery. Trends Pharmacol. Sci. 31, 124-130
8. Terrillon, S., and Bouvier, M. (2004) Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5, 30-34
9. Evans, R. M., You, H., Hameed, S., Altier, C., Mezghrani, A., Bourinet, E., and Zamponi, G. W. (2010) Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J. Biol. Chem. 285, 1032-1040
10. Fujita, W., Gomes, I., and Devi, L. A. (2014) Mu-Delta opioid receptor heteromers: New pharmacology and novel therapeutic possibilities. Br. J. Pharmacol. 10.1111/bph.12663
11. van Rijn, R. M., Whistler, J. L., and Waldhoer, M. (2010) Opioid-receptor-heteromer-specific trafficking and pharmacology. Curr. Opin. Pharmacol. 10, 73-79
12. Wang, D., Sun, X., Bohn, L. M., and Sadée, W. (2005) Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol. Pharmacol. 67, 2173-2184
13. Jordan, B. A., Gomes, I., Rios, C., Filipovska, J., and Devi, L. A. (2003) Functional interactions between mu opioid and α2A-adrenergic receptors. Mol. Pharmacol. 64, 1317-1324
14. Tan, M., Walwyn, W. M., Evans, C. J., and Xie, C. W. (2009) p38 MAPK and β-arrestin 2 mediate functional interactions between endogenous micro-opioid and α2A-adrenergic receptors in neurons. J. Biol. Chem. 284, 6270-6281
15. Vilardaga, J. P., Nikolaev, V. O., Lorenz, K., Ferrandon, S., Zhuang, Z., and Lohse, M. J. (2008) Conformational cross-talk between α2A-adrenergic and mu-opioid receptors controls cell signaling. Nat. Chem. Biol. 4, 126-131
16. Pfeiffer, M., Koch, T., Schröder, H., Laugsch, M., Höllt, V., and Schulz, S. (2002) Heterodimerization of somatostatin and opioid receptors crossmodulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 277, 19762-19772
17. Pfeiffer, M., Kirscht, S., Stumm, R., Koch, T., Wu, D., Laugsch, M., Schröder, H., Höllt, V., and Schulz, S. (2003) Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. J. Biol. Chem. 278, 51630-51637
18. Roumy, M., Lorenzo, C., Mazères, S., Bouchet, S., Zajac, J. M., and Mollereau, C. (2007) Physical association between neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activity. J. Biol. Chem. 282, 8332-8342
19. Moulédous, L., Froment, C., Dauvillier, S., Burlet-Schiltz, O., Zajac, J. M., and Mollereau, C. (2012) GRK2 protein-mediated transphosphorylation contributes to loss of function of mu-opioid receptors induced by neuropeptide FF (NPFF2) receptors. J. Biol. Chem. 287, 12736-12749
20. 2+channels in rat spinal ganglion neurones. Neuroreport 7, 2979-2981
21. Roumy, M., Garnier, M., and Zajac, J. M. (2003) Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurones. Neurosci. Lett. 348, 159-162
22. Roumy, M., and Zajac, J. (1999) Neuropeptide FF selectively attenuates the effects of nociceptin on acutely dissociated neurons of the rat dorsal raphe nucleus. Brain Res. 845, 208-214
23. Kersanté, F., Mollereau, C., Zajac, J. M., and Roumy, M. (2006) Anti-opioid activities of NPFF(1) receptors in a SH-SY5Y model. Peptides 27, 980-989
24. Mollereau, C., Mazarguil, H., Zajac, J. M., and Roumy, M. (2005) Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol. Pharmacol. 67, 965-975
25. Dupouy, V., and Zajac, J. M. (1995) Effects of neuropeptide FF analogs on morphine analgesia in the nucleus raphe dorsalis. Regul. Pept. 59, 349-356
26. Dupouy, V., and Zajac, J. M. (1997) Neuropeptide FF receptors control morphine-induced analgesia in the parafascicular nucleus and the dorsal raphe nucleus. Eur. J. Pharmacol. 330, 129-137
27. Yang, H. Y., Tao, T., and Iadarola, M. J. (2008) Modulatory role of neuropeptide FF system in nociception and opiate analgesia. Neuropeptides 42, 1-18
28. Kersanté, F., Wang, J. Y., Chen, J. C., Mollereau, C., and Zajac, J. M. (2011) Anti-opioid effects of neuropeptide FF receptors in the ventral tegmental area. Neurosci. Lett. 488, 305-309
29. Kotlinska, J., Pachuta, A., Dylag, T., and Silberring, J. (2007) Neuropeptide FF (NPFF) reduces the expression of morphine- but not of ethanol-induced conditioned place preference in rats. Peptides 28, 2235-2242
30. Marchand, S., Betourne, A., Marty, V., Daumas, S., Halley, H., Lassalle, J. M., Zajac, J. M., and Frances, B. (2006) A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides 27, 964-972
31. Moulédous, L., Frances, B., and Zajac, J. M. (2010) Modulation of basal and morphine-induced neuronal activity by a NPFF(2) selective agonist measured by c-Fos mapping of the mouse brain. Synapse 64, 672-681
32. Moulédous, L., Mollereau, C., and Zajac, J. M. (2010) Opioid-modulating properties of the neuropeptide FF system. Biofactors 36, 423-429
33. Brady, A. E., and Limbird, L. E. (2002) G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal. 14, 297-309
34. Hur, E. M., and Kim, K. T. (2002) G protein-coupled receptor signalling and cross-talk: achieving rapidity and specificity. Cell Signal. 14, 397-405
35. Maudsley, S., Martin, B., and Luttrell, L. M. (2005) The origins of diversity and specificity in g protein-coupled receptor signaling. J. Pharmacol. Exp. Ther. 314, 485-494
36. Salomé, L., Cazeils, J. L., Lopez, A., and Tocanne, J. F. (1998) Characterization of membrane domains by FRAP experiments at variable observation areas. Eur. Biophys. J. 27, 391-402
37. Briddon, S. J., and Hill, S. J. (2007) Pharmacology under the microscope: the use of fluorescence correlation spectroscopy to determine the properties of ligand-receptor complexes. Trends Pharmacol. Sci. 28, 637-645
38. Daumas, F., Destainville, N., Millot, C., Lopez, A., Dean, D., and Salomé, L. (2003) Confined diffusion without fences of a G-protein-coupled receptor as revealed by single particle tracking. Biophys. J. 84, 356-366
39. Baker, A., Saulière, A., Dumas, F., Millot, C., Mazères, S., Lopez, A., and Salomé, L. (2007) Functional membrane diffusion of G-protein coupled receptors. Eur. Biophys. J. 36, 849-860
40. Barnett-Norris, J., Lynch, D., and Reggio, P. H. (2005) Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci. 77, 1625-1639
41. Choquet, D., and Triller, A. (2003) The role of receptor diffusion in the organization of the postsynaptic membrane. Nat. Rev. Neurosci. 4, 251-265
42. Destainville, N., Dumas, F., and Salomé, L. (2008) What do diffusion measurements tell us about membrane compartmentalisation? Emergence of the role of interprotein interactions. J. Chem. Biol. 1, 37-48
43. Lopez, A., and Salomé, L. (2009) Membrane functional organisation and dynamic of mu-opioid receptors. Cell. Mol. Life Sci. 66, 2093-2108
44. Qiu, Y., Wang, Y., Law, P. Y., Chen, H. Z., and Loh, H. H. (2011) Cholesterol regulates micro-opioid receptor-induced β-arrestin 2 translocation to membrane lipid rafts. Mol. Pharmacol. 80, 210-218
45. Saulière, A., Gaibelet, G., Millot, C., Mazères, S., Lopez, A., and Salomé, L. (2006) Diffusion of the mu opioid receptor at the surface of human neuroblastoma SH-SY5Y cells is restricted to permeable domains. FEBS Lett. 580, 5227-5231
46. Saulière-Nzeh Ndong, A. N., Millot, C., Corbani, M., Mazères, S., Lopez, A., and Salomé, L. (2010) Agonist-selective dynamic compartmentalization of human Mu opioid receptor as revealed by resolutive FRAP analysis. J. Biol. Chem. 285, 14514-14520
47. Vukojević, V., Ming, Y., D'Addario, C., Hansen, M., Langel, U., Schulz, R., Johansson, B., Rigler, R., and Terenius, L. (2008) Mu-opioid receptor activation in live cells. FASEB J. 22, 3537-3548
48. Calizo, R. C., and Scarlata, S. (2013) Discrepancy between fluorescence correlation spectroscopy and fluorescence recovery after photobleaching diffusion measurements of G-protein-coupled receptors. Anal. Biochem. 440, 40-48
49. Golebiewska, U., Johnston, J. M., Devi, L., Filizola, M., and Scarlata, S. (2011) Differential response to morphine of the oligomeric state of mu-opioid in the presence of delta-opioid receptors. Biochemistry 50, 2829-2837
50. Baker, A. M., Saulière, A., Gaibelet, G., Lagane, B., Mazères, S., Fourage, M., Bachelerie, F., Salomé, L., Lopez, A., and Dumas, F. (2007) CD4 interacts constitutively with multiple CCR5 at the plasma membrane of living cells. A fluorescence recovery after photobleaching at variable radii approach. J. Biol. Chem. 282, 35163-35168
51. Talmont, F., Garcia, L. P., Mazarguil, H., Zajac, J. M., and Mollereau, C. (2009) Characterization of two novel tritiated radioligands for labelling Neuropeptide FF (NPFF(1) and NPFF(2)) receptors. Neurochem. Int. 55, 815-819
52. Soumpasis, D. M. (1983) Theoretical analysis of fluorescence photobleaching recovery experiments. Biophys. J. 41, 95-97
53. Lopez, A., Dupou, L., Altibelli, A., Trotard, J., and Tocanne, J. F. (1988) Fluorescence recovery after photobleaching (FRAP) experiments under conditions of uniform disk illumination. Critical comparison of analytical solutions, and a new mathematical method for calculation of diffusion coefficient D. Biophys. J. 53, 963-970
54. Lippincott-Schwartz, J., Snapp, E., and Kenworthy, A. (2001) Studying protein dynamics in living cells. Nat. Rev. Mol. Cell Biol. 2, 444-456
55. Reits, E. A., and Neefjes, J. J. (2001) From fixed to FRAP: measuring protein mobility and activity in living cells. Nat. Cell. Biol. 3, E145-E147
56. Kazmi, S. M., and Mishra, R. K. (1989) Identification of α2-adrenergic receptor sites in human retinoblastoma (Y-79) and neuroblastoma (SHSY5Y) cells. Biochem. Biophys. Res. Commun. 158, 921-928
57. McDonald, R. L., Vaughan, P. F., Beck-Sickinger, A. G., and Peers, C. (1995) Inhibition of Ca2+ channel currents in human neuroblastoma (SH-SY5Y) cells by neuropeptide Y and a novel cyclic neuropeptide Y analogue. Neuropharmacology 34, 1507-1514
58. Vaughan, P. F., Peers, C., and Walker, J. H. (1995) The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release. Gen. Pharmacol. 26, 1191-1201
59. Calebiro, D., Rieken, F., Wagner, J., Sungkaworn, T., Zabel, U., Borzi, A., Cocucci, E., Zürn, A., and Lohse, M. J. (2013) Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc. Natl. Acad. Sci. U.S.A. 110, 743-748
60. Kasai, R. S., Suzuki, K. G., Prossnitz, E. R., Koyama-Honda, I., Nakada, C., Fujiwara, T. K., and Kusumi, A. (2011) Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. J. Cell Biol. 192, 463-480
61. Lambert, N. A. (2010) GPCR dimers fall apart. Sci. Signal. 3, pe12
62. Vilardaga, J. P., Agnati, L. F., Fuxe, K., and Ciruela, F. (2010) G-protein-coupled receptor heteromer dynamics. J. Cell Sci. 123, 4215-4220
63. Fairbanks, C. A., and Wilcox, G. L. (1999) Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J. Pharmacol. Exp. Ther. 288, 1107-1116
64. Roumy, M., and Zajac, J. M. (1998) Neuropeptide FF, pain and analgesia. Eur. J. Pharmacol. 345, 1-11
65. Zhang, Y. Q., and Limbird, L. E. (2004) Hetero-oligomers of α2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles. Biochem. Soc. Trans. 32, 856-860
66. Berglund, M. M., Schober, D. A., Esterman, M. A., and Gehlert, D. R. (2003) Neuropeptide Y Y4 receptor homodimers dissociate upon agonist stimulation. J. Pharmacol. Exp. Ther. 307, 1120-1126
67. Kilpatrick, L. E., Briddon, S. J., and Holliday, N. D. (2012) Fluorescence correlation spectroscopy, combined with bimolecular fluorescence complementation, reveals the effects of β-arrestin complexes and endocytic targeting on the membrane mobility of neuropeptide Y receptors. Biochim. Biophys. Acta 1823, 1068-1081
68. Pucadyil, T. J., Kalipatnapu, S., Harikumar, K. G., Rangaraj, N., Karnik, S. S., and Chattopadhyay, A. (2004) G-protein-dependent cell surface dynamics of the human serotonin1A receptor tagged to yellow fluorescent protein. Biochemistry 43, 15852-15862
69. Zheng, H., Chu, J., Qiu, Y., Loh, H. H., and Law, P. Y. (2008) Agonist-selective signaling is determined by the receptor location within the membrane domains. Proc. Natl. Acad. Sci. U.S.A. 105, 9421-9426
70. Moulédous, L., Merker, S., Neasta, J., Roux, B., Zajac, J. M., and Mollereau, C. (2008) Neuropeptide FF-sensitive confinement of mu opioid receptor does not involve lipid rafts in SH-SY5Y cells. Biochem. Biophys. Res. Commun. 373, 80-84
71. Kersanté, F., Moulédous, L., Zajac, J. M., and Mollereau, C. (2010) Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins. Neurochem. Int. 56, 768-773
72. Carta, M., Opazo, P., Veran, J., Athané, A., Choquet, D., Coussen, F., and Mulle, C. (2013) CaMKII-dependent phosphorylation of GluK5 mediates plasticity of kainate receptors. EMBO J. 32, 496-510
73. Specht, C. G., Grünewald, N., Pascual, O., Rostgaard, N., Schwarz, G., and Triller, A. (2011) Regulation of glycine receptor diffusion properties and gephyrin interactions by protein kinase C. EMBO J. 30, 3842-3853
74. Law, P. Y., Erickson-Herbrandson, L. J., Zha, Q. Q., Solberg, J., Chu, J., Sarre, A., and Loh, H. H. (2005) Heterodimerization of mu- and deltaopioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J. Biol. Chem. 280, 11152-11164
75. Levitt, E. S., Purington, L. C., and Traynor, J. R. (2011) Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol. Pharmacol. 79, 461-471
76. Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., and Granier, S. (2012) Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485, 321-326
77. Saffman, P. G., and Delbrück, M. (1975) Brownian motion in biological membranes. Proc. Natl. Acad. Sci. U.S.A. 72, 3111-3113
78. Dorsch, S., Klotz, K. N., Engelhardt, S., Lohse, M. J., and Bünemann, M. (2009) Analysis of receptor oligomerization by FRAP microscopy. Nat. Methods 6, 225-230
79. Briddon, S. J., Gandía, J., Amaral, O. B., Ferré, S., Lluís, C., Franco, R., Hill, S. J., and Ciruela, F. (2008) Plasma membrane diffusion of G proteincoupled receptor oligomers. Biochim. Biophys. Acta 1783, 2262-2268